Clinical Trials Directory

Trials / Sponsors / Celyad Oncology SA

Celyad Oncology SA

Industry · 13 registered clinical trials — 3 currently recruiting.

StatusTrialPhaseStarted
RecruitingStudy of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
Unresectable Metastatic Colorectal Cancer
Phase 12021-11-22
Active Not RecruitingSafety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma
Relapse/Refractory Multiple Myeloma
Phase 12020-11-16
RecruitingStudy in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Reco
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Phase 12019-11-25
WithdrawnEPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2
AML, Adult, Myelodysplastic Syndromes
Phase 12018-12-01
RecruitingalloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Ant
Unresectable Metastatic Colorectal Cancer
Phase 12018-11-28
CompletedDEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2
AML, MDS
Phase 1 / Phase 22018-09-18
TerminatedHepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal
Colon Cancer Liver Metastasis
Phase 12017-10-11
UnknownDose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses
Colon Cancer Liver Metastasis
Phase 12017-08-07
UnknownCongestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-2) Trial - THE CHART-2 TRIAL
Heart Failure
Phase 32017-06-01
UnknownA Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications
Acute Myeloid Leukemia/Myelodysplastic Syndrome, Multiple Myeloma (MM)
Phase 1 / Phase 22016-12-01
CompletedSafety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
Phase 12015-03-01
CompletedSafety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.
Heart Failure
Phase 32012-11-01
CompletedC-Cure Clinical Trial
Heart Failure Class II or III
Phase 2 / Phase 32008-12-01